Achilles Therapeutics plc (ACHL)
| Market Cap | 236.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 40.60M |
| EPS (ttm) | -5.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,391 |
| Open | 5.81 |
| Previous Close | 5.84 |
| Day's Range | 5.52 - 5.90 |
| 52-Week Range | 5.45 - 18.95 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 19.83 (+240.1%) |
| Est. Earnings Date | Nov 10, 2021 |
About ACHL
Achilles Therapeutics is a clinical stage immuno-oncology biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumors. Our platform enables us to identify mutations formed early in the development of a cancer that give rise to antigens. We refer to this novel class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, we have developed a proprietary bioinformatic platform called PELEUS. This platform employs sophisticated statistical algorithms trained on the uniqu...
Financial Performance
Financial StatementsNews
Achilles Therapeutics to Present at Upcoming Investor Conferences
LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...
Achilles Therapeutics Announces Grant of US and European Patents
LONDON, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announce...
Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights
– Presentations of translational science data at AACR and ASCO illustrate crucial path to potency assay –
Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer
- Patient enrolled at the Moffitt Cancer Center, FL where Dr. Benjamin Creelan is the Principal Investigator -
Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights
- Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -
Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference
LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced...
Achilles Therapeutics Appoints Julie O'Neill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Adviso...
LONDON, United Kingdom, May 03, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors,...
Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study a...
LONDON, April 10, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today present...
Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering
LONDON, April 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...
UK-based Achilles Therapeutics unveils US$175.5mln IPO at Nasdaq debut
Achilles Therapeutics plc (NASDAQ: ACHL) announced the pricing of its IPO on the Nasdaq that will raise US$175.5mln (£127.8mln). The clinical-stage biopharma, which is developing precision T cell therap...
Achilles Therapeutics Announces Pricing of Initial Public Offering
LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announc...
UK-based biotech Achilles Therapeutics files for a $100 million US IPO
Achilles Therapeutics, a Phase 1/2 biotech developing precision T cell therapies for solid tumors, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
Achilles Therapeutics IPO Registration Document (S-1)
Achilles Therapeutics plc has filed to go public with an IPO on the NASDAQ.